Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;50(11):1301-9.
doi: 10.1177/0091270009358708. Epub 2010 Feb 9.

Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum

Sara Eyal  1 , Joong D Kim, Gail D Anderson, Megan L Buchanan, Debra A Brateng, Darcy Carr, David E Woodrum, Thomas R Easterling, Mary F Hebert
Affiliations

Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum

Sara Eyal et al. J Clin Pharmacol. 2010 Nov.

Abstract

The objectives were to evaluate the time course for atenolol pharmacokinetics in lactating women postpartum and to quantify atenolol plasma concentrations in the women's 3- to 4-month-old nursing infants. Data were collected during 1 dosing interval from lactating women treated with atenolol for therapeutic reasons, at 2 to 4 weeks (n = 32), 3 to 4 months (n = 22), and 6 to 8 months (n = 17) postpartum. A single blood sample was collected from 15 nursing infants (3-4 months of age) of the mothers participating in the study. At 2 to 4 weeks, 3 to 4 months, and 6 to 8 months postpartum, atenolol infant doses, relative to the mother's weight-adjusted dose, were 14.6% ± 7.6%, 8.3% ± 5.2% and 5.9% ± 2.9%, respectively. Over this time, maternal atenolol pharmacokinetics did not change to a clinically significant extent. Atenolol concentrations were below assay quantification limits (<10 ng/mL) in the plasma of all 3- to 4-month-old nursing infants studied. These findings support the careful use of atenolol during breastfeeding, because in the vast majority of healthy, term infants, atenolol concentrations will be too low to be clinically relevant. Premature infants and those with kidney disease require further study. Infant exposure depends on maternal dose and decreases during the first 6 to 8 months postpartum.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Amount of atenolol excreted daily in breast milk for 2–4 weeks (n=32), 3–4 months (N=22), and 6-8 months (n=15) postpartum. Error bars indicate standard deviations. Numbers in the bars indicate the number of subjects in each dose and study day group.
Figure 2
Figure 2
Correlation between atenolol dose (A) or atenolol maternal plasma AUC (B) and atenolol AUC in breast milk for 2–4 weeks (n=32), 3–4 months (N=22), and 6-8 months (n=15) postpartum.
Figure 3
Figure 3
Average atenolol concentration–time profiles in plasma and breast milk (n=15) for subjects treated with atenolol twice daily (adjusted to 50 mg/day) 2–4 weeks postpartum (A), 3–4 months postpartum (B), and 6-8 months postpartum (C). Error bars represent standard deviations.
See this image and copyright information in PMC

References

    1. American Academy of Pediatrics, Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–779. - PubMed
    1. TenorminR product labeling. AstraZeneca; Wilmington DE: Apr 08, 2008.
    1. Schmimmel MS, Eidelman AJ, Wilschanski MA, Shaw D, Ogilvie RJ, Koren G. Toxic effects of atenolol consumed during breast feeding. J Pediatr. 1989;114:476–478. - PubMed
    1. Fowler MB, Brudenell M, Jackson G, Holt DW. Essential hypertension and pregnancy: successful outcome with atenolol. Br J Clin Pract. 1984;38:73–74. - PubMed
    1. White WB, Andreoli JW, Wong SH, Cohn RD. Atenolol in human plasma and breast milk. Obstet Gynecol. 1984;63(3 Suppl):42S–44S. - PubMed

Publication types